Pyrilutamide

Pyrilutamide is a nonsteroidal antiandrogen (NSAA) that was never marketed. It is a selective androgen receptor antagonist, similar to flutamide and bicalutamide, and was researched for potential use in the treatment of androgen-dependent conditions like acne, hirsutism, and androgenic alopecia, but was not developed for medical use.

Pharmacology

Pyrilutamide acts as a selective antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It competes with these androgens for binding to the AR and thereby prevents them from exerting their biological effects in the body. As such, pyrilutamide is classified as a nonsteroidal antiandrogen (NSAA).

History

Pyrilutamide was first described in the literature in 1980 and was investigated for potential medical use in the 1980s and early 1990s. However, for reasons that are not entirely clear, development of pyrilutamide was discontinued, and it was never marketed.

See also

• List of nonsteroidal antiandrogens
• Discovery and development of nonsteroidal antiandrogens

‎